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Abstract
Background
In sub-Saharan Africa, diabetes is a growing burden, yet little is known about its preva-
lence, risk factors, and complications. To address these gaps and help inform public health
efforts aimed at prevention and treatment, we conducted a community-based study
assessing diabetes epidemiology.
Methods and Findings
We conducted a stratified, cluster-designed, serial cross-sectional household study from
2014–2015 in the Kilimanjaro Region, Tanzania. We used a three-stage cluster probability
sampling method to randomly select individuals. To estimate prevalence, we screened
individuals for glucose impairment, including diabetes, using hemoglobin A1C. We also
screened for hypertension and obesity, and to assess for potential complications, individu-
als with diabetes were assessed for retinopathy, neuropathy, and nephropathy. We
enrolled 481 adults from 346 urban and rural households. The prevalence of glucose
impairment was 21.7% (95% CI 15.2–29.8), which included diabetes (5.7%; 95% CI 3.37–
9.47) and glucose impairment with increased risk for diabetes (16.0%; 95% CI 10.2–24.0).
Overweight or obesity status had an independent prevalence risk ratio for glucose
impairment (2.16; 95% CI 1.39–3.36). Diabetes awareness was low (35.6%), and few indi-
viduals with diabetes were receiving biomedical treatment (33.3%). Diabetes-associated
complications were common (50.2%; 95% CI 33.7–66.7), including renal (12.0%; 95% CI
4.7–27.3), ophthalmic (49.6%; 95% CI 28.6–70.7), and neurological (28.8%; 95% CI 8.0–
65.1) abnormalities.
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Conclusions
In a northern region of Tanzania, diabetes is an under-recognized health condition, despite
the fact that many people either have diabetes or are at increased risk for developing diabe-
tes. Most individuals were undiagnosed or untreated, and the prevalence of diabetes-asso-
ciated complications was high. Public health efforts in this region will need to focus on
reducing modifiable risk factors, which appear to include obesity, as well as early detection
that includes increasing awareness. These findings highlight a growing urgency of diabetes
prevention in this region as well as the need for treatment, including management of
complications.
Introduction
Non-communicable diseases (NCDs) are a growing global epidemic that disproportionately
affect economic and health outcomes in low- and middle-income countries (LMICs) [1, 2]. In
order to address this disparity, it will be critical to reduce the burden of NCDs in sub-Saharan
Africa (SSA) where they are now a leading cause of death among adults [1–3].
In SSA, where more than 900 million people live, expanding population growth is juxta-
posedwith rapid urbanization [4, 5]. In the context of NCDs such as diabetes, the accompa-
nying lifestyle and dietary changes that parallel this demographic transition mean that millions
are and will be at risk [5–7]. As such, current estimates portend that the prevalence of diabetes
and glucose impairment in SSA could nearly double by the year 2045, which means that more
than 40 million people would be living with diabetes in SSA. Moreover, nearly three-fourths of
diabetes-related deaths occur in economically-productive persons under the age of 60 years
[6].
One of the most significant barriers in addressing diabetes in SSA is the limited understand-
ing of its epidemiology including community prevalence, modifiable risk factors such as diet
and obesity, and complications arising from under-recognition or under-treatment [3, 6, 8–
10]. At this time, the prevalence of undiagnoseddiabetes in SSA is estimated to be higher than
in any other region of the world with as many as two-thirds of cases being unrecognized [6,
10]. Furthermore, despite the highmorbidity and mortality of diabetes, the micro-vascular
complications resulting from diabetes in SSA are not well-studied due to the lack of compara-
ble epidemiological data [6, 10–12].
To address these gaps, the Comprehensive Kidney Disease Assessment for Risk Factors,
epidemiology, Knowledge, and Attitudes (CKD-AFRiKA) study was conducted in the Kiliman-
jaro Region of northern Tanzania between 2014 and 2015 [13, 14]. Its overall objective was to
understand the population-based epidemiology, awareness, and practices associated with
NCDs, including diabetes. As part of the CKD-AFRiKA Study, we conducted a cross-sectional,
community-based study of diabetes to assess its prevalence, modifiable risk factors including
obesity, and end-organ micro-vascular complications, including nephropathy, retinopathy,
and neuropathy.
Methods
Ethics Statement
The study protocol was approved by Duke University Institutional ReviewBoard
(#Pro00040784), the Kilimanjaro ChristianMedical College (KCMC) Ethics Committee
(EC#502), and the National Institute for Medical Research (NIMR) in Tanzania. Written
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informed consent (by signature or thumbprint) was obtained from all participants, and all par-
ticipants with abnormal findings received counselling, educational pamphlets, and reimburse-
ment with referral for follow-up.
Study Setting
We conducted a stratified, cluster-designed, serial cross-sectional household survey between
January and June 2014 and betweenMarch and June 2015 in the Kilimanjaro Region of Tanza-
nia. The adult regional population is more than 900,000 people of whom 35% live in urban set-
tings. Most adults have only a primary school level of education (77%). The regional HIV
prevalence is 3–5%. The largest ethnic group is the Chagga tribe followed by the Pare, Sambaa,
and Maasai tribes. Swahili is the major language [15, 16].
The region comprises seven districts, and our study was conducted in two of these districts,
Moshi Urban and Moshi Rural, which served as strata for our sampling scheme (Fig 1). The
districts are divided into administrative wards, and each ward is further sub-divided into
neighbourhoods,which are the smallest governmental administrative unit in Tanzania. Neigh-
bourhoods range in size from 500 to 5000 people [16].
Sampling Methods
We used a three-stage cluster sampling method, stratified by urban and rural districts.We used
a random-number generator to select twenty nine neighbourhoodswithin the Moshi Urban
and Moshi Rural districts.We based the random neighborhood sampling on probability pro-
portional to size according to the 2012 national census [16]. From the twenty-nine neighbor-
hoods, we then randomly selected the starting point for each sampling area (37 in total) using
geographic coordinates randomly generated by Arc Global Information Systems (ArcGIS),
v10.2.2 (Environmental Systems Research Institute, Redlands, CA). From the randomly-
selected geographic starting point, we then chose households based on a coin-flip and die-roll-
ing technique (S1 Appendix). All non-pregnant adults (age 18 years old) living in the
Fig 1. Study Setting. Map showing the sampling area of Moshi Urban and Moshi Rural in the Kilimanjaro
Region of Northern Tanzania. Source: Stanifer JW, Maro V, Egger J, Karia F, Thielman N, Turner EL, et al.
The Epidemiology of Chronic Kidney Disease in Northern Tanzania: A Population-Based Survey. PLOS
ONE. 2015;10(4):e0124506. Open access distribution under the Creative Commons Attribution, Non-
Commercial, No Derivatives 4.0 International License
doi:10.1371/journal.pone.0164428.g001
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selected households were recruited. To be eligible each adult had to be a permanent resident
(living nine months each year in Tanzania) or a citizen of Tanzania. To ensure that the pro-
tocol was strictly adhered to, the principal investigator (JWS) regularly accompanied the sur-
veyors and frequently conducted anonymous shadowing.
We targeted between 15 and 25 participants per sampling area based on the requirements of
the CKDAFRiKA study, which was designed to estimate the community prevalence of chronic
kidney disease (CKD), diabetes, and hypertension with a precision of 5% when accounting for
the cluster-design effect, assuming a disease prevalence up to 20% and an intra-cluster correla-
tion (ICC) coefficient of 0.05. To reduce non-response rates, we attempted a minimum of two
additional visits during off-hours (evenings and weekends) and multiple phone calls using
mobile phone numbers. When available, we collected demographic data for the non-respond-
ers including age, gender, and occupation.
Data Collection
Between January and June 2014, each participant completed a demographic and medical his-
tory survey, was measured for anthropomorphic data, and was tested for CKD, diabetes melli-
tus, and hypertension. Disease awareness was defined as giving a self-reported disease history
and subsequently testing positive during the screening process.
Anthropomorphic data included height, weight, and bodymass index (BMI). Normal
weight was defined as a BMI of 20 to 24.9 kg/m2. Overweightwas defined as a BMI25 kg/m2
and obesity was defined as a BMI30 kg/m2.
Hemoglobin (Hb) A1c was measured from a fingerstick whole blood sample using the
Bayer A1c Now+ point-of-care device (Bayer Healthcare LLC; Sunnyvale, CA). Quality control
measures were performedweekly according to the manufacturer’s recommendation. Glucose
impairment was defined as an HbA1C>6.0% in the presence or absence of ongoing treatment
with anti-hyperglycemic medications. Diabetes mellitus was defined as an HbA1c level7.0%
or current known use of anti-hyperglycemic medications for the purpose of treating diabetes.
Participants with an HbA1C between 6.0% and 6.9% in the absence of treatment with anti-
hyperglycemicmedications were considered to have glucose impairment with an increased risk
for developing diabetes [17].
CKD was defined according to the Kidney Disease Improving Global OutcomesWorking
Group guidelines [18]. To estimate glomerular filtration rate (eGFR), we used the Modification
of Diet in Renal Disease (MDRD) equation without the race factor. A urine albumin greater
than 30 mg/dL in the absence of gross haematuria or an ongoing urinary tract infection as con-
firmed by urinalysis (SiemensMultistix 10G Urinalysis test strips) was considered positive.
Urine albumin was detectedwith a Siemens MicroAlbustix (Siemens Healthcare Diagnostics,
Inc.; Tarrytown, NY) from a mid-stream urine sample. All positive urine albumin results were
confirmedwith a repeat measurement from a first-morning void, mid-stream urine sample
more than 48 hours from the initial measurement. Quality control measures were performed
weekly on each open and new bottle of urine dipsticks according to the manufacturer’s recom-
mendation. The serum creatinine was measured using the Cobas Integra 400 Plus (RocheDiag-
nostics; Basel Switzerland) at the Kilimanjaro Christian Research Institute Biotechnology
Laboratory. The laboratory is known in the region for its high quality results, and it participates
fully in international external quality assurance programs including the College of American
Pathologists and the United Kingdom External Quality Assessment Service.All laboratory
investigations were conducted according to GoodClinical Laboratory Practice standards.
We measured blood pressure using the automated Omron HEM-712 sphygmomanometer
(Omron Healthcare, Inc.; Bannockburn, IL), which has an adjustable cuff size. The machine
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was calibrated monthly during data collection.All participants were seated in an erect position
with feet flat on the floor for a minimum of five minutes before measurements. Hypertension
was defined as a single blood pressure measurement of greater than 160/100 mmHg, a two-
time average measurement of greater than 140/90 mmHg, or current known use of anti-hyper-
tensive medications.
BetweenMarch and June 2015, participants with diabetes mellitus were also screened for
retinopathy and peripheral neuropathy. A trained retinal photographer captured fundus images
of both eyes using a Topcon retinal camera (TRCNW8S; Topcon Corporation, Tokyo, Japan)
following pupil dilation with topical tropicamide 1%. Each digital photograph was graded for ret-
inopathy and maculopathy according to the minimum dataset outlined by the English andWales
National ScreeningCommittee [19]. Two consultant ophthalmologists independently graded
each digital photograph and any disagreements were resolved by joint consensus. Retinopathy
was graded as absent (R0), background (R1), pre-proliferative (R2), or proliferative (R3). Maculo-
pathy was graded as absent (M0) or present (M1). For each participant, retinopathy and maculo-
pathy were each scored according to the more severely diseased eye.
A single physician assessed for distal, lower-extremity peripheral neuropathy using a scored
combination of vibration perception, pinprick sensation, and Achilles ankle reflexes (S1
Appendix) [20]. Based on these assessments, a total score (0–8) was reported for each partici-
pant. We considered peripheral neuropathy present if the total score was4 [20].
Data Analysis and Data Management
Data were analyzed using STATAv.13 (STATA Corp., College Station, TX). Continuous vari-
ables were summarized by the median and inter-quartile range (IQR). Categorical variables
were summarized using counts and percentages.We used a Chi-squared goodness-of-fit test or
Fisher’s exact test to compare differences between groups. To account for the design effect on
variance due to cluster sampling, we first estimated the level of clustering which occurred at
each of the three sampling levels (neighborhood, sampling area, and household) by fitting a
mixed effectsmodel with separate random intercepts for neighborhood, sampling area, and
household for diabetes and glucose impairment separately. In these models, after accounting
for the neighborhoodclustering, very little variance in the clustering (<15%) remained at the
sampling area level and household level, which indicated to us that most of the variation in
these outcomes was explained at the individual- and neighborhood-levels.As such, we esti-
mated the ICC for the neighborhoodclusters only. ICC coefficients for the binary outcomes,
diabetes and glucose impairment with increased risk for diabetes, using a one-way random
effects analysis of variance (ANOVA) estimator [21, 22].
To account for the design effect at each sampling level, all prevalence and model estimates
were performedwithin the ‘svy’ command in STATA, which allowed us to account for variance
due to the complex three-level hierarchal survey design. Crude and adjusted prevalence risk
ratios (PRR) were estimated using generalized linear models with a log link. All p-values are
two-sided at a 0.05 significance level.
To address potential non-response bias in the community-based prevalence estimates, we
explored difference in age, gender, occupation, and education between the study population
and the regional population, and we sample-adjusted all the prevalence estimates using age-
and gender-frequencyweights based on the 2012 urban and rural district-level census data
[16]. To address potential non-response bias in the estimation of prevalence for diabetes-asso-
ciated complications, we explored differences in age, gender, HbA1c values, BMI, and serum
creatinine between participants who did and did not present for follow-up assessment for reti-
nopathy and neuropathy.
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A secondary aim of the analysis was to explore the association between glucose impairment
and overweight or obesity status. Step-wise model specificationwas carried out by using sub-
stantive knowledge of potential confounding factors potentially associated with risk of glucose
impairment and being overweight or propoobese, such as age, gender, and ethnicity. Candidate
models were then compared by calculation of the mean squared error of the effect.We did not
include lifestyle or environmental factors, such as urbanicity, occupation, or education in our
models due to a priori assumptions about their potential upstream causal association with
overweight or obesity status.
All data were collected on paper and then electronically entered into and managed using
REDCap electronic data capture tools hosted at Duke University. REDCap is a secure, web-
based application designed to support data capture for research studies [23]. All data were veri-
fied after electronic data entry by an independent reviewer to ensure accuracy.
Results
We enrolled 481 adults from 346 households (Table 1). The median age was 45.0 years (IQR
35–59). The majority of participants lived in an urban district (n = 370; 77.0%), were women
(n = 358; 74.4%), ethnically Chagga (n = 288; 59.9%), and had a primary school level of educa-
tion (n = 349; 72.6%). Participants were most frequently occupied as farmers or daily wage-
earners (n = 199; 41.4%). Many participants reported ongoing use of alcohol (n = 198; 41.2%).
The household non-response rate was 15.0% and the individual non-response rate was
20.6%. Compared to the regional population [16], men (p<0.001) and young adults 18–39
years old (p = 0.001) were more likely to be non-responders in our study, and the proportion
of participants with a secondary or post-secondary education (22.4%) was higher than the
regional average (14.6%) (p = 0.02). We observedno significant differences in occupation
between the responders and non-responders (p = 0.64). Among participants with diabetes, 35
(77.8%) were screened for retinopathy and 33 (73.3%) were screened for neuropathy. Reasons
for non-response in this group were refusal, lost to contact, and illness. There were no signifi-
cant differences in age, gender, HbA1c, BMI, or serum creatinine (p>0.05 for all) between
those with diabetes who responded and those who did not respond for follow-up assessment.
The overall prevalence of glucose impairment was 21.7% (95% CI 15.2–29.8), which
included diabetes and glucose impairment with increased risk for diabetes. The community
prevalence of diabetes was 5.7% (95% CI 3.37–9.47), and the prevalence of glucose impairment
with increased risk for diabetes was 16.0% (95% CI 10.2–24.0). The neighborhood-level ICC
coefficient for diabetes was<0.001, and the neighborhood-level ICC coefficient for glucose
impairment with increased risk for diabetes was 0.031.
Individuals with glucose impairment were older, more commonly occupied as professionals,
had hypertension, or had an overweight or obese BMI (p<0.01 for all), and they were less likely
to be consuming alcohol (p = 0.01). Among the 45 individuals with diabetes, 30 (66.7%) were
female, most had a primary school level of education or less (n = 26; 56.8%) and lived in an
urban setting (n = 39; 86.7%), and many were occupied as professionals (n = 16; 35.7%)
(Table 1). The median age was 57 years (IQR 48–67). The median HbA1C of participants with
diabetes was 9.8% (IQR 7.5–11). Over half of the individuals with diabetes also had hyperten-
sion (n = 24; 53.3%), and almost three-quarters (n = 33; 73.3%) were overweight or obese. The
median BMI of individuals with diabetes was 27.8 (IQR 24.7–30.1); however, several individu-
als (n = 12; 26.7%) had a normal weight BMI (n = 8; 17.8%) or underweight BMI (n = 4; 8.9%).
Among the 84 individuals who had glucose impairment with an increased risk for diabetes, 65
(77.4%) were female, and the median age was 51.0 years (IQR 37.5–60). The median HbA1C
was 6.3% (IQR 6.2–6.5), and the median BMI was 29.1 (IQR 25.7–32.0).
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Overweight or obesity status was an independent risk factor for glucose impairment (Fig 2).
In univariable regression modelling, compared with normal weight individuals, there was an
increased prevalence risk (PRR 2.16; 95% CI 1.39–3.36) of glucose impairment associated with
being overweight or obese (BMI25). Adjustment for potential confounders in multi-variable
modelling, including age, gender, ethnicity, and ongoing biomedicine use did not substantially
Table 1. Participant characteristics by Diabetes and Diabetes Risk Status; CKD-AFRiKA study population, 2015;N = 481.
Variable Participants
Overall(n = 481) No Glucose Impairment(n = 352) Glucose Impairment(n = 129) p-value±
Increased risk for diabetes(n = 84) Diabetes(n = 45)
Gender 0.81
Male 123 (25.6%) 89 (25.3%) 19 (22.6%) 15 (33.3%)
Female 358 (74.4%) 263 (74.7%) 65 (77.4%) 30 (66.7%)
Age <0.01
18–39 years old 172 (35.8%) 143 (40.6%) 24 (28.6%) 5 (11.1%)
40–59 years old 191 (39.7%) 135 (38.4%) 37 (44.1%) 19 (42.2%)
60+ years old 118 (24.5%) 74 (21.0%) 23 (27.4%) 21 (46.7%)
Setting (District) 0.50
Rural 111 (23.1%) 84 (23.9%) 21 (25.0%) 6 (13.3%)
Urban 370 (76.9%) 268 (76.1%) 63 (75.0%) 39 (86.7%)
Ethnicity 0.36
Chagga 288 (59.9%) 217 (61.7%) 45 (53.6%) 26 (57.8%)
Pare 66 (13.7%) 43 (12.2%) 19 (22.6%) 4 (8.9%)
Sambaa 27 (5.6%) 22 (6.3%) 3 (3.6%) 2 (4.4%)
Other* 100 (20.8%) 70 (19.9%) 17 (20.2%) 13 (28.9%)
Education 0.75
None 31 (6.4%) 21 (6.0%) 4 (4.8%) 6 (13.3%)
Primary 349 (72.6%) 260 (73.9%) 63 (75.0%) 26 (57.8%)
Secondary 74 (15.4%) 52 (14.8%) 12 (14.3%) 10 (22.2%)
Post-Secondary 27 (5.6%) 19 (5.3%) 5 (6.0%) 3 (6.7%)
Occupation <0.01
Unemployed 74 (15.4%) 52 (14.8%) 15 (17.9%) 7 (15.6%)
Farmer/Wage Earner 199 (41.4%) 157 (44.6%) 32 (38.1%) 10 (22.2%)
Small Business/Vendors 158 (32.8%) 121 (34.4%) 25 (29.8%) 12 (26.7%)
Professional† 50 (10.4%) 22 (6.3%) 12 (14.3%) 16 (35.7%)
Ongoing Alcohol Use 198 (41.2%) 157 (44.6%) 33 (39.3%) 8 (17.8%) 0.01
Ongoing Tobacco Use 50 (10.4%) 42 (11.9%) 7 (8.3%) 1 (2.2%) 0.07
Co-Morbid Health
Conditions
Hypertension 149 (31.0%) 96 (27.3%) 29 (34.5%) 24 (53.3%) <0.01
BMI (median) 26.2 25.1 29.1 27.8 <0.01
Underweight 59 (12.3%) 51 (45.5%) 4 (4.7%) 4 (8.9%)
Normal weight 143 (29.7%) 122 (34.6%) 13 (15.5%) 8 (17.8%)
Overweight/Obese 279 (58.0%) 179 (50.9%) 67 (79.8%) 33 (73.3%)
HbA1C (median) 5.7 5.5 6.3 9.8 <0.01
±p-value comparing differences by presence or absence of glucose impairment
*Other ethnicities includes Maasai, Luguru, Kilindi, Kurya, Mziguwa, Mnyisanzu, Rangi, Jita, Nyambo, and Kaguru.
† Professional included any salaried position (e.g. nurse, teacher, government employee, etc.) and retired persons.
doi:10.1371/journal.pone.0164428.t001
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change (<5%) the prevalence risk of glucose impairment associated with overweight or obese
BMI (S2 Appendix).
Diabetes awareness was low among those found to have diabetes (n = 16; 35.6%), and few
individuals with diabetes were receiving biomedical treatment at the time of the initial data col-
lection (n = 15; 33.3%). The prevalence of adults with diabetes reporting traditional medicine
use was 77.1% (95% CI 58.0–89.2%).
Many individuals had end-organ micro-vascular complications associated with diabetes
(Table 2). The prevalence of renal complications among individuals with diabetes was 12.0%
(95% CI 4.7–27.3) and included reduced eGFR and albuminuria. The prevalence of ophthal-
mologic complications was 49.6% (95% CI 28.6–70.7) and included retinopathy and maculopa-
thy. The prevalence of neurologic complications manifested as peripheral neuropathy was
Fig 2. Forest Plot. Unadjusted and adjusted prevalence risk ratios, with corresponding 95% CI, for glucose
impairment by body mass index (BMI) category. *Adjusted for age, gender, and ethnicity.
doi:10.1371/journal.pone.0164428.g002
Table 2. Prevalence of end-organ micro-vascular complications present in adults with diabetes from Kilimanjaro (n = 45*; CKD-AFRiKA 2015).
Complications N (%) Prevalence± (%; 95% CI)
Renal
Reduced eGFR‡ 4 (8.9%) 3.8% (1.0–14.0)
Albuminuria 11 (24.4%) 11.3% (4.4–26.0)
Albuminuria or reduced eGFR 12 (26.7%) 12.0% (4.7–27.3)
Ophthalmological
Background retinopathy 12 (34.3%) 36.2% (14.8–64.8)
Pre-proliferative retinopathy 3 (8.6%) 12.3% (3.1–38.2)
Proliferative retinopathy 2 (5.7%) 1.1% (0.2–5.7)
Maculopathy 9 (25.7%) 24.6% (10.3–48.1)
Retinopathy or Maculopathy 17 (48.6%) 49.6% (28.6–70.7)
Neurological
Peripheral neuropathy 7 (21.2%) 28.8% (8.0–65.1)
1 complication 25 (55.6%) 52.3% (34.8–69.3)
2 complications 9 (20.0%) 33.4% (10.7–67.8)
*Among the 45 participants with diabetes, 45 (100%) were assessed for renal complications, 35 (78%) for ophthalmological complications, and 33 (73%) for
neurological complications.
±Sample-adjusted, weighted prevalence among individuals with diabetes.
‡60 ml/min/1.73m2 by Modification of Diet in Renal Disease formula without the race factor.
doi:10.1371/journal.pone.0164428.t002
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28.8% (95% CI 8.0–65.1). The prevalence of individuals with diabetes having at least one com-
plication was 52.3% (95% CI 34.8–69.3), and the prevalence of having multiple complications
(2) was 33.4% (95% CI 10.7–67.8).
Discussion
Among a randomly-selected, community-based sample from northern region of Tanzania, we
observeda high prevalence of glucose impairment, including diabetes, which was strongly asso-
ciated with obesity. Despite a burden that is comparable to several middle- and high-income
countries, awareness was low, and few people were receiving biomedical treatments. Concur-
rently, we observed a high prevalence of diabetes-associated complications, including retinopa-
thy, neuropathy, and nephropathy [6, 24–26].
Globally, obesity is a major risk factor for diabetes, and its prevalence is growing rapidly in
LMICs [6, 27]. In SSA, rates of obesity are among the fastest growing in the world [28]. Our
findings, which highlight the significant association between obesity and glucose impairment
in parts of the Kilimanjaro Region of Tanzania, extend the findings from others studies across
different regions of SSA showing obesity as an important, modifiable risk factor for diabetes [7,
29–34]. We also observed a high prevalence of co-morbid conditions, such as hypertension
and CKD among adults with diabetes, and this further emphasizes that public health efforts
addressing diabetes should incorporate shared, modifiable risk factors for several NCDs.
As in high-income countries, diabetes in SSA is a major risk factor for death and disability
from cardiovascular disease, stroke, CKD, and infections, particularly soft tissue and blood-
stream infections [7, 8, 10, 35]. However, despite the health consequences of diabetes in SSA,
most national health systems are unprepared for the burden [3, 36]. In Tanzania, very few pri-
mary-level health centres have services directed towards NCDs such as clinical providers, diag-
nostics, treatments, and referral capacities [37]. Consistent with this, few participants in our
study had been previously diagnosedwith diabetes or were receiving biomedical treatments for
diabetes, while diabetes-associated complications were common.
Notwithstanding the high prevalence of undiagnosed and untreated diabetes in parts of the
Kilimanjaro Region, we observed an even higher prevalence of community members with glu-
cose impairment who are at increased risk for developing diabetes. This finding indicates that a
substantially greater disease burden may underlie what is currently known about diabetes in
the region. Furthermore, considering the high prevalence of diabetes-associated complications,
which are costly, resource-intensive to treat, and associated with poor health outcomes includ-
ing death, this further highlights the importance of both primary and secondary prevention of
diabetes through comprehensive epidemiology reporting including screening of high-risk pop-
ulations, risk mitigation by reducing modifiable risk factors, preparation of health systems, and
increasing public health and primary care capacity [31, 38].
Our study is among the first community-based studies assessing glucose impairment, diabe-
tes, and diabetes-associated complications in SSA, and in Tanzania, to our knowledge, there
are only two other community-based studies on diabetes in the last 15 years [29, 35, 39–43].
Moreover, our study is among the first to use HbA1C as a diagnostic test for diabetes in SSA,
and we assessed for diabetes-associated complications using clinically meaningful parameters
which may bemore readily available in clinical or research settings across the region.
Despite these strengths, there are also limitations of our study. Given the cross-sectional
design, causal relationships between diabetes and measured risk factors or commonmicro-vas-
cular complications cannot be drawn. Misclassification of disease around the cut-off points for
disease definitionsmay also be present although we expect any misclassification to be non-dif-
ferential. The Bayer A1c Now+ point-of-care device that we used to measure A1c has not been
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validated in this population, and we defined diabetes using values based on parameters
assigned from different populations. As such, it is unknownwhat cut-off values should be used
to define diabetes and diabetes risk in this population or how these point-of-care values corre-
spond to laboratory basedmeasurements of HbA1c in this population. Considering the sub-
stantial and growing burden of diabetes and other NCDs in the region, validated, accessible
point-of-care devices used for diagnosis and monitoring are urgently needed [7, 44].
Furthermore, we were unable to distinguish between insulin-dependent or Type I diabetes
and Type II diabetes. In our study, several individuals with diabetes were normal or under-
weight, which may suggest that insulin-dependent or Type I diabetes is also an important
health burden in the region, and further epidemiologywork is needed to understand this
potentially important distinction. Finally, non-response bias can be introduced when the
response rate is low and when there is a substantial difference between responders and non-
responders. To address non-response bias that may have arisen from differences between the
respondents and non-respondents, we used sample-balanced weights for age and gender, and
we explored potential differences in characteristics between the two groups. However, the addi-
tional potential for informative missingness in the retinopathy and neuropathy measurements
means that our estimates for these diabetes-associated complications may be under-estimated
as illness was a reported reason for non-response.
In conclusion, in parts of northernTanzania, diabetes is an under-recognizedhealth condition
despite that fact that many people either have diabetes or are at increased risk for developing dia-
betes.Most individuals with diabetes or at risk for diabetes were undiagnosedor untreated, and
the prevalence of diabetes-associated complications, including retinopathy, neuropathy, and
nephropathy, was high. Public health efforts will need to address prevention with a focus on
reducingmodifiable risk factors, which appears to include obesity, as well as early detection
aimed at increasing awareness. These findings highlight a growing urgency of diabetes prevention
in this region as well as the need for treatment, includingmanagement of complications.
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